May 12, 2010 – Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee
NDA – naproxcinod (NicOx)
Agenda: On May 12, 2010, the committees will discuss new drug application (NDA) 22-478, naproxcinod 375 milligram capsule, sponsored by NicOx S.A., a non-steroidal anti-inflammatory drug (NSAID) product indicated for the treatment of the signs and symptoms of osteoarthritis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment